Search

Your search keyword '"Kristian, Alexandr"' showing total 139 results
Start Over Author "Kristian, Alexandr"
139 results on '"Kristian, Alexandr"'

1. Liver X receptors induce antiproliferative effects in basal‐like breast cancer

Author

Haugen, Mads Haugland, primary, von der Lippe Gythfeldt, Hedda, additional, Egeland, Eivind Valen, additional, Svartdal Normann, Lisa, additional, Pandya, Abhilash D., additional, Vedin, Lise‐Lotte, additional, Juell, Siri, additional, Tenstad, Ellen, additional, Øy, Geir Frode, additional, Kristian, Alexandr, additional, Marangoni, Elisabetta, additional, Sørlie, Therese, additional, Steffensen, Knut, additional, Mælandsmo, Gunhild Mari, additional, and Engebraaten, Olav, additional

Published
2023
Full Text
View/download PDF

3. Supplementary Figure Legends 1-4 from B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation

Author

Liu, Hao, primary, Tekle, Christina, primary, Chen, Yih-Wen, primary, Kristian, Alexandr, primary, Zhao, Yuhua, primary, Zhou, Ming, primary, Liu, Zixing, primary, Ding, Yan, primary, Wang, Bin, primary, Mælandsmo, Gunhild Mari, primary, Nesland, Jahn Marthin, primary, Fodstad, Oystein, primary, and Tan, Ming, primary

Published
2023
Full Text
View/download PDF

13. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer

Author

Jin, Yang, Qu, Su, Tesikova, Martina, Wang, Ling, Kristian, Alexandr, Mælandsmo, Gunhild M., Kong, Haiying, Zhang, Tianzhou, Jerónimo, Carmen, Teixeira, Manuel R., Yuca, Erkan, Tekedereli, Ibrahim, Gorgulu, Kivanc, Alpay, Neslihan, Sood, Anil K., Lopez-Berestein, Gabriel, Danielsen, Håvard E., Ozpolat, Bulent, and Saatcioglu, Fahri

Published
2013

14. STAMP2 increases oxidative stress and is critical for prostate cancer

Author

Jin, Yang, Wang, Ling, Qu, Su, Sheng, Xia, Kristian, Alexandr, Mælandsmo, Gunhild M, Pällmann, Nora, Yuca, Erkan, Tekedereli, Ibrahim, Gorgulu, Kivanc, Alpay, Neslihan, Sood, Anil, Lopez‐Berestein, Gabriel, Fazli, Ladan, Rennie, Paul, Risberg, Bjørn, Wæhre, Håkon, Danielsen, Håvard E, Ozpolat, Bulent, and Saatcioglu, Fahri

Published
2015
Full Text
View/download PDF

22. MOESM1 of Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist

Author

Kathinka Pitman, Kine Bakke, Kristian, Alexandr, and Malinen, Eirik

Abstract

Additional file 1: Figure S1. All adequate AIFs for 90 animals. The median AIF used in the Tofts modelling of all tumours is drawn in blue. Figure S2. Sample DCE-MRI data for four different tumours. Pre-contrast T1 weighted central axial image with the tumour delineated (left), parametric maps of Ktrans, νe and νB and r2 (middle), and time-concentration curves with Tofts fitted model for median data representing the tumour (right). Figure S3. DCE-MRI derived data observed for HBCx34 (left column(s)) and HBCx39 (right column(s)) tumours at baseline, 1 and 6 days posttreatment; Gd-DOTA concentration in the A wash-in and B wash-out phase C νe, D νB and E tumour volume based on DCE-MRI images. Figure S4. RMME model estimates with standard error bars shown in the positive direction. Table S1. Estimated coefficients with standard errors and p-values for univariate RMME of DCE-MRI derived data. Grey outlines indicate significant (p

Published
2019
Full Text
View/download PDF

23. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma

Author

Saelen Marie, Ree Anne, Kristian Alexandr, Fleten Karianne, Furre Torbjørn, Hektoen Helga, and Flatmark Kjersti

Subjects
Rectal cancer, Vorinostat, Fluoropyrimidine, Hypoxia, Radiation, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The histone deacetylase inhibitor vorinostat is a candidate radiosensitizer in locally advanced rectal cancer (LARC). Radiosensitivity is critically influenced by hypoxia; hence, it is important to evaluate the efficacy of potential radiosensitizers under variable tissue oxygenation. Since fluoropyrimidine-based chemoradiotherapy (CRT) is the only clinically validated regimen in LARC, efficacy in combination with this established regimen should be assessed in preclinical models before a candidate drug enters clinical trials. Methods Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively. Radiosensitizing effects of vorinostat in combination with capecitabine were assessed by evaluation of tumor growth delay in two colorectal carcinoma xenografts models. Results Under hypoxia, radiosensitization by vorinostat was demonstrated in vitro in terms of decreased clonogenicity and in vivo as inhibition of tumor growth. Adding vorinostat to capecitabine-based CRT increased radiosensitivity of xenografts in terms of inhibited tumor growth. Conclusions Vorinostat sensitized colorectal carcinoma cells to radiation under hypoxia in vitro and in vivo and improved therapeutic efficacy in combination with capecitabine-based CRT in vivo. The results encourage implementation of vorinostat into CRT in LARC trials.

Published
2012
Full Text
View/download PDF

24. Targeted Alpha Therapy with anti-HER2 Thorium-227 Antibody-chelator Conjugates (HER2-TTCs) in Mouse Xenograft Models with Varying Levels of HER2 Expression and Resistance to Current State-of-the-art Therapies

Author

Karlsson, Jenny, primary, Cruciani, Veronique, additional, Cuthbertson, Alan S., additional, Grant, Derek, additional, Ellingsen, Christine, additional, Kristian, Alexandr, additional, Hagemann, Urs B., additional, Schatz, Christoph, additional, Bjerke, Roger M., additional, Ryan, Olav, additional, and Mumberg, Dominik, additional

Published
2019
Full Text
View/download PDF

25. In vivo 31P MRSI for metabolic profiling of human breast cancer xenografts

Author

Esmaeili, Morteza, Moestue, Siver Andreas, Hamans, Bob C., Veltien, Andor, Kristian, Alexandr, Engebråten, Olav, Mælandsmo, Gunhild, Gribbestad, Ingrid S, Bathen, Tone, and Heerschap, Arend

Abstract

Purpose To study cancer associated with abnormal metabolism of phospholipids, of which several have been proposed as biomarkers for malignancy or to monitor response to anticancer therapy. We explored 3D 31P magnetic resonance spectroscopic imaging (MRSI) at high magnetic field for in vivo assessment of individual phospholipids in two patient-derived breast cancer xenografts representing good and poor prognosis (luminal- and basal-like tumors). Materials and Methods Metabolic profiles from luminal-like and basal-like xenograft tumors were obtained in vivo using 3D 31P MRSI at 11.7T and from tissue extracts in vitro at 14.1T. Gene expression analysis was performed in order to support metabolic differences between the two xenografts. Results In vivo 31P MR spectra were obtained in which the prominent resonances from phospholipid metabolites were detected at a high signal-to-noise ratio (SNR >7.5). Metabolic profiles obtained in vivo were in agreement with those obtained in vitro and could be used to discriminate between the two xenograft models, based on the levels of phosphocholine, phosphoethanolamine, glycerophosphocholine, and glycerophosphoethanolamine. The differences in phospholipid metabolite concentration could partly be explained by gene expression profiles. Conclusion Noninvasive metabolic profiling by 3D 31P MRSI can discriminate between subtypes of breast cancer based on different concentrations of choline- and ethanolamine-containing phospholipids. © 2014 Wiley Periodicals, Inc. This is the authors' manuscript to the article.

Published
2015

30. Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts.

Author

Kristian, Alexandr, Holtedahl, Jon, Torheim, Turid, Futsaether, Cecilia, Hernes, Eivor, Engebraaten, Olav, Mælandsmo, Gunhild, Malinen, Eirik, Holtedahl, Jon Erik, and Mælandsmo, Gunhild M

Subjects
*POSITRON emission tomography, *BREAST cancer patients, *XENOGRAFTS, *TUMOR growth, *DOXORUBICIN, *CANCER chemotherapy, *DIAGNOSIS, *ANIMAL experimentation, *ANTINEOPLASTIC agents, *BIOLOGICAL models, *BREAST tumors, *CELL lines, *CELL physiology, *DEOXY sugars, *MICE, *RADIOPHARMACEUTICALS
Abstract

Purpose: Non-invasive response monitoring can potentially be used to guide therapy selection for breast cancer patients. We employed dynamic 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG PET) to evaluate changes in three breast cancer xenograft lines in mice following three chemotherapy regimens.Procedures: Sixty-six athymic nude mice bearing bilateral breast cancer xenografts (two basal-like and one luminal-like subtype) underwent three 60 min [18F]FDG PET scans. Scans were performed prior to and 3 and 10 days after treatment with doxorubicin, paclitaxel, or carboplatin. Tumor growth was monitored in parallel. A pharmacokinetic compartmental model was fitted to the tumor uptake curves, providing estimates of transfer rates between the vascular, non-metabolized, and metabolized compartments. Early and late standardized uptake values (SUVE and SUVL, respectively); the rate constants k 1, k 2, and k 3, and the intravascular fraction v B were estimated. Changes in tumor volume were used as a response measure. Multivariate partial least-squares regression (PLSR) was used to assess if PET parameters could model tumor response and to identify PET parameters with the largest impact on response.Results: Treatment responders had significantly larger perfusion-related parameters (k 1 and k 2) and lower metabolism-related parameter (k 3) than non-responders 10 days after the start of treatment. These findings were further supported by the PLSR analysis, which showed that k 1 and k 2 at day 10 and changes in k 3 explained most of the variability in response to therapy, whereas SUVL and particularly SUVE were of lesser importance.Conclusions: Overall, rate parameters related to both tumor perfusion and metabolism were associated with tumor response. Conventional metrics of [18F]FDG uptake such as SUVE and SUVL apparently had little relation to tumor response, thus necessitating full dynamic scanning and pharmacokinetic analysis for optimal evaluation of chemotherapy-induced changes in breast cancers. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts

Author

Grinde, Maria T, primary, Skrbo, Nirma, additional, Moestue, Siver A, additional, Rødland, Einar A, additional, Borgan, Eldrid, additional, Kristian, Alexandr, additional, Sitter, Beathe, additional, Bathen, Tone F, additional, Børresen-Dale, Anne-Lise, additional, Mælandsmo, Gunhild M, additional, Engebraaten, Olav, additional, Sørlie, Therese, additional, Marangoni, Elisabetta, additional, and Gribbestad, Ingrid S, additional

Published
2014
Full Text
View/download PDF

42. B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation

Author

Liu, Hao, primary, Tekle, Christina, additional, Chen, Yih-Wen, additional, Kristian, Alexandr, additional, Zhao, Yuhua, additional, Zhou, Ming, additional, Liu, Zixing, additional, Ding, Yan, additional, Wang, Bin, additional, Mælandsmo, Gunhild Mari, additional, Nesland, Jahn Marthin, additional, Fodstad, Oystein, additional, and Tan, Ming, additional

Published
2011
Full Text
View/download PDF

49. Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study

Author

Kristian Alexandr, Olaf Sørensen, Per Olaf Ekstrøm, Harald Olsen, Anders Mikal Andersen, Karl Erik Giercksky, and Kjersti Flatmark

Subjects
Male, Microdialysis, Cancer Research, Mitomycin, Pharmacology, lcsh:RC254-282, Rats, Nude, Pharmacokinetics, In vivo, medicine, Genetics, Distribution (pharmacology), Animals, Tissue Distribution, Infusions, Intravenous, Antibiotics, Antineoplastic, business.industry, Mitomycin C, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Tinidazole, Bioavailability, Rats, Oncology, Hyperthermic intraperitoneal chemotherapy, Peritoneum, business, Injections, Intraperitoneal, medicine.drug, Research Article
Abstract

Background Mitomycin C is a chemotherapeutic agent used in the treatment of peritoneal surface malignancies, administered as hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. Pharmacokinetic studies have been based on analyses of blood, urine and abdominal perfusate, but actual tissue concentrations of the drug have never been determined. Microdialysis is an established method for continuous monitoring of low-molecular substances in tissues, and in the present study microdialysis of mitomycin C was studied in vitro and in vivo. Methods Using in vitro microdialysis, relative recovery was determined when varying drug concentration, temperature and perfusion flow rate. In vivo microdialysis was performed in rats to verify long-term stability of relative recovery in four compartments (vein, peritoneum, extraperitoneal space and hind leg muscle). Subsequently, intravenous and intraperitoneal bolus infusion experiments were performed and pharmacokinetic parameters were calculated. Results In vitro, compatibility of mitomycin C and microdialysis equipment was demonstrated, and relative recovery was stable over an adequate concentration range, moderately increased by raising medium temperature and increased when flow rate was reduced, all according to theory. In vivo, stable relative recovery was observed over seven hours. Mitomycin C exhibited fast and even distribution in rat tissues, and equal bioavailability was achieved by intravenous and intraperitoneal infusion. The half-life of mitomycin C calculated after intravenous infusion was 40 minutes. Conclusions Mitomycin C concentration can be reliable monitored in vivo using microdialysis, suggesting that this technique can be used in pharmacokinetic studies of this drug during hyperthermic intraperitoneal chemotherapy.

Published
2010

50. In Vivo 31P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.

Author

Esmaeili, Morteza, Moestue, Siver A., Hamans, Bob C., Veltien, Andor, Kristian, Alexandr, Engebråten, Olav, Mælandsmo, Gunhild M., Gribbestad, Ingrid S., Bathen, Tone F., and Heerschap, Arend

Abstract

Purpose To study cancer associated with abnormal metabolism of phospholipids, of which several have been proposed as biomarkers for malignancy or to monitor response to anticancer therapy. We explored 3D 31P magnetic resonance spectroscopic imaging (MRSI) at high magnetic field for in vivo assessment of individual phospholipids in two patient-derived breast cancer xenografts representing good and poor prognosis (luminal- and basal-like tumors). Materials and Methods Metabolic profiles from luminal-like and basal-like xenograft tumors were obtained in vivo using 3D 31P MRSI at 11.7T and from tissue extracts in vitro at 14.1T. Gene expression analysis was performed in order to support metabolic differences between the two xenografts. Results In vivo 31P MR spectra were obtained in which the prominent resonances from phospholipid metabolites were detected at a high signal-to-noise ratio (SNR >7.5). Metabolic profiles obtained in vivo were in agreement with those obtained in vitro and could be used to discriminate between the two xenograft models, based on the levels of phosphocholine, phosphoethanolamine, glycerophosphocholine, and glycerophosphoethanolamine. The differences in phospholipid metabolite concentration could partly be explained by gene expression profiles. Conclusion Noninvasive metabolic profiling by 3D 31P MRSI can discriminate between subtypes of breast cancer based on different concentrations of choline- and ethanolamine-containing phospholipids. J. Magn. Reson. Imaging 2015;41:601-609. © 2014 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results